Due to the inclusion criteria, patients were generally diagnosed with an IDH 1/2 wildtype glioblastoma, and 32% (n = 19) showed a promoter methylation of the MGMT gene (Table 1). The gene discussed is MGMT; the disease is glioblastoma.